Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2026
Pharma
Enhertu successor, ESMO, Gilead—Fierce Pharma Asia
Fierce provides a deep dive into the hunt for the next Enhertu in breast cancer. ESMO 2026 data featured Chinese assets backed by Big Pharma.
Angus Liu
Oct 30, 2026 8:45am
Fierce Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
Merck sees ‘pretty consistent’ data in sac-TMT’s 1st global ph. 3
Oct 26, 2026 11:30am
Bristol CMO touts more ph. 3 wins for bispecific ADC iza-bren
Oct 26, 2026 3:30am
ESMO: AZ, Hutchmed’s Orpathys combo shows post-Tagrisso power
Oct 25, 2026 11:30am
Akeso CEO looks for more ivonescimab combos after AZ deal
Oct 25, 2026 11:30am
